X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company intends to use the net proceeds for the development of INT230-6, a formulation consisting of its proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine.
Lead Product(s): 2-hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate,Cisplatin
Therapeutic Area: Oncology Product Name: INT230-6
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Benchmark Company
Deal Size: $19.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 30, 2023
Details:
INT230-6 is designed for direct intratumoral injection, composed of two proven, potent anti-cancer agent, cisplatin and vinblastine, and penetration enhancer molecule that help disperse potent cytotoxic drugs throughout tumors for diffusion into cancer cells.
Lead Product(s): Cisplatin,Vinblastine Sulfate,Pembrolizumab
Therapeutic Area: Oncology Product Name: INT230-6
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Details:
Translational analysis of IMM60 confirms that PORT-2 activates iNKT cells, NK cells and dendritic cells, supporting the mechanism of action to stimulate both the adaptive and innate immune system.
Lead Product(s): IMM60,Pembrolizumab
Therapeutic Area: Oncology Product Name: IMM60
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Portage Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Data show INT230-6 (Cisplatin), is designed for direct intratumoral injection is well tolerated and elicits both direct tumor killing and immune activating effects in a variety of solid tumors.
Lead Product(s): Cisplatin,Vinblastine Sulfate,Pembrolizumab
Therapeutic Area: Oncology Product Name: INT230-6
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
INT230-6, Intensity’s lead proprietary investigational product candidate, is designed for direct intratumoral injection was discovered using Intensity’s proprietary DfuseRx℠ technology platform.
Lead Product(s): INT230-6
Therapeutic Area: Oncology Product Name: INT230-6
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2021
Details:
Data in the first poster show that INT230-6, monotherapy or in combination with pembrolizumab, is well tolerated and elicits both direct tumor killing and abscopal effects. The second presentation reports similar results of INT230-6 with or without ipilimumab in sarcoma.
Lead Product(s): Cisplatin,Vinblastine Sulfate,Ipilimumab
Therapeutic Area: Oncology Product Name: INT230-6
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
The Ottawa Hospital and The Ontario Institute for Cancer Research (OICR) to conduct a Phase II Randomized, Window of Opportunity (WOO) trial evaluating clinical and biological effects of intratumoral INT230-6 vs. no treatment in early stage breast cancer.
Lead Product(s): Cisplatin,Vinblastine Sulfate,Salcaprozate Sodium
Therapeutic Area: Oncology Product Name: INT230-6
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ottawa Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 24, 2021
Details:
Local delivery of INT230-6 as monotherapy into tumors induced an immune response with increases of activated CD4+ and CD8+ T-cells in the tumor without any immune-related adverse events.
Lead Product(s): Cisplatin,Vinblastine Sulfate,Ipilimumab
Therapeutic Area: Oncology Product Name: INT230-6
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
The scPharmaceuticals management team will discuss the FUROSCIX® development plan. FUROSCIX® is an investigational, proprietary formulation of furosemide that is administered subcutaneously via a wearable on-body, drug delivery system, for outpatient self-administration.
Lead Product(s): Cisplatin,Vinblastine Sulfate,Ipilimumab
Therapeutic Area: Oncology Product Name: INT230-6
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
The paper describes INT230-6, a novel combination of cisplatin and vinblastine formulated with a unique amphiphilic diffusion enhancer molecule that non-covalently interacts with payloads to increase intratumoral drug dispersion into solid tumors.
Lead Product(s): Cisplatin,Vinblastine Sulfate
Therapeutic Area: Oncology Product Name: INT230-6
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
